所有的研究员都需要在适当的保护时间内参加临床或基础研究. There are multiple research opportunities available including NIH-funded basic science and clinical research. 研究员还可以选择根据自己的兴趣定制研究.

研究经验的目的是让学员学习设计和执行研究的合理方法, 以及对研究数据的正确解读和综合，将其应用于患者护理. 研究员还获得了如何设计和解释研究的知识, the responsible use of informed consent, 正确的研究方法和数据的解释，并参与实际项目.

Research Setting

我们是美国国立卫生研究院资助的研究实验室，专注于生物标志物的进步，以帮助诊断, prognostication, and selection of treatment modalities for Rheumatological disorders. 我们还与来自三家不同医院的不同患者群体合作. 患者人口统计资料的多样性为常见和罕见风湿病的临床研究提供了大量的来源材料.

Research Timeline in Training

First Year Fellow:

• 奖学金获得者将探索当前的研究项目，以帮助制定他们在第二年想要从事的项目.
• 鼓励研究员研究有趣的临床病例，并在风湿病大查房和实验室会议上发表.
• 研究员参与各种研究中获取和输入患者, and may elect to spend up to a month on a specific project.
• 研究员将接受花旗关于人类研究对象的伦理和利益冲突研究培训，并参加关于研究方面的迷你课程.

Second Year Fellow:

• 我们鼓励学员在第一年结束前完成大部分选修课，这样他们就可以在第二年投入更多的时间进行研究.
• 研究员应准备他们的研究活动，以供介绍和出版. They are also expected to publish at least one scientific paper, book chapter, abstract, case reports in a peer-reviewed journal, 同行评议的绩效改进和/或提交同行评议的资金或同行评议的摘要, state, 或者在奖学金期间参加全国性的专业会议.

Third Year Fellow:

• 对于那些有兴趣进行深入研究的人，可选择第三年.
• A specific project will be tailored to the fellow’s interest, 通常取决于他们在前两年在一个类似项目中的经验和进展.
• Eighty-five percent time is protected for research; 15% of their time is devoted to clinical duties, 包括每周半天门诊的连续性门诊护理经验, one month of inpatient consult year, 参加实验室会议/期刊俱乐部和每周风湿病学会议

大多数研究员在同行评审的出版物中担任合著者

Publications from Former Fellows

Liu, Y, Yu J, Oaks Z, Marchena-Mendez I, Francis L, Bonilla E, Aleksiejuk P, Patel J, Banki K, Landas SK, Perl A. (2015)肝损伤与自身免疫和疾病活动性的生物标志物相关，并代表系统性红斑狼疮患者的器官系统受累. Clin Immunology. 160(2):319-327. PMID:26160213

Lai, ZW, Marchena-Mendez I, Perl A. (2015)红斑狼疮伴抗磷脂综合征患者的氧化应激和Treg消耗. Clin Immunology. 158(2):148-52. PIMD:25862984

Lai, ZW, Borsuk, R., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Francis, F., Tily, H., Bartos, A., Faraone, S.V., Phillips, P.E. and Perl. A. (2013). mTOR激活触发系统性红斑狼疮患者双阴性T细胞的IL-4产生和坏死死亡. J. Immunol. 191: 2236-2246. doi: 10.4049/jimmunol.1301005

Garcia, R.J., Francis, L., Dawood, M, Lai, Z-W., Faraone, S.V., and Perl, A. (2013) SLE患者的注意缺陷和多动障碍评分升高并对NAC治疗有反应. Arth. Rheum. 65: 1313-1318. PMID: 23400548

Lai, Z-W, Hanczko, R., Bonilla, E, Caza, T.N., Clair, B., Bartos, A., Miklossy, G, Jimah, J., Doherty, E, Tily, H., Francis, L, Garcia, R., Dawood, M., Yu, J., Ramos, I., Coman, I., Faraone, S.V., Phillips, P.E. and Perl, A. (2012). n -乙酰半胱氨酸通过阻断狼疮患者T细胞中的mTOR降低疾病活动性. Arth. Rheum. 64: 2937-2946. PMID:22549432

Tily, H., Banki, K., Hoffman, G.S. and Perl. A. (2010)家族性Sneddon综合征狼疮抗凝剂检测及抗凝成功. Ann. Rheum. Dis. 69: 775-776.

Francis, L. and Perl. A. (2010) Infection in systemic lupus erythematosus: friend or foe? Int. J. Clin. Rheumatol. 5:59-74.

Soforo, E., Baumgartner, M., Francis, L., Allam, F., Phillips, P.E., and Perl, A. (2010) Induction of systemic lupus erythematosus with TNF blockers. J. Rheumatol. 37:204-205.

Tily, HI and Perl, A. (2009)淋巴水肿:肿瘤坏死因子抑制剂的矛盾效应——病例报告及文献综述. BMJ Case Reports [doi:10.1136/bcr.07.2008.0520]

Perl, A., Fernandez, D., Telarico, T., Francis, L. and Phillips, P.E. (2009)狼疮患者的T细胞和b细胞信号生物标志物和治疗靶点. Curr. Opin. Rheumatol. 21: 454-464.

Francis, L. and Perl. A. (2009) Pharmacotherapy of SLE. Expert. Opin. Pharmacother. 10: 1481-1494.

Fernandez, D.R. Telarico, T., Bonilla, E., Li, Q., Banerjee, S., Middleton, F.A., Phillips, P.E.,  Crow, M.K., Oess, S., Muller-Esterl, W., and Perl, A. (2009) mTOR的激活通过HRES-1/ rab4调节的溶酶体降解控制狼疮T细胞中TCRζ的丢失. J. Immunol. 182: 2063-2073.

Perl, A., Nagy, G.,  Koncz, A., Gergely, P., Fernandez, D., Doherty, E., Telarico, T., Bonilla, E. and Phillips, P.E. (2008) HRES-1内源性逆转录病毒在SLE中的分子模拟和免疫调节作用. Autoimmunity, 41:287-297.

 Vyshkina, T., Sylvester, A., Sadiq, S., Bonilla, E., Canter, J., Perl, A. and Kalman, B.(2008)常见线粒体DNA变异与多发性硬化症和系统性红斑狼疮的关系. Clin. Immunol. 129:31-35.

Vyshkina, T., Sylvester, A., Sadiq, S., Bonilla, E., Perl, A. and Kalman, B.(2008)多发性硬化症和系统性红斑狼疮的CCL基因. J. Neuroimmunol. 200:145-152.

Pullmann, R. Jr., Bonilla, E., Phillips, P.E., Middleton, F.A. and Perl, A. (2008) HRES-1内源性逆转录病毒的单倍型与系统性红斑狼疮的发展和疾病表现有关. Arth. Rheum. 58: 532-540.

Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, and Perl A. (2008) Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin. Rheumatol. 27:129-31.

Bonilla, E., Francis, L., Allam, F., Ogrinc, M., Neupane, H., Phillips, P.E., and Perl, A. (2007)免疫荧光显微镜检测系统性红斑狼疮患者的抗核抗体反应性优于荧光珠. Clin. Immunol. 124:18-21

Bonilla, E., Lee, Y.Y., Phillips, P.E., and Perl, A. (2007) 1例2型糖尿病患者开始依那西普治疗后低血糖. Ann. Rheum. Dis. 66:1688.

Quintero M, Mirza N, Chang H, Perl A. (2006)与中枢神经系统原发性脉管炎相关的抗磷脂抗体综合征:两例活检证实病例的报告. Ann. Rheum. Dis. 65 :408‑9

Fernandez, D., Bonilla, E., Mirza, N, Niland, B. and Perl, A. (2006)在系统性红斑狼疮患者中，雷帕霉素降低疾病活动性并使t细胞激活诱导的钙通量正常化. Arth. Rheum. 54: 2983-2988.

Fernandez, D., Bonilla, E., Phillips, P.E. and Perl, A. (2006)系统性红斑狼疮信号异常作为潜在的药物靶点. Endocrin, Metabolic & Immune Disorders - Drug Targets. 6:305-311

Mukhopadhyay, S., Mousa, S., George, B.R. and Perl, A. (2004) Palpable purpura, polyarthritis, and abdominal pain. Med. J. Aust. 180:121-122.